|Bid||98.50 x 4000|
|Ask||98.52 x 800|
|Day's Range||97.38 - 101.67|
|52 Week Range||36.15 - 151.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.19|
Concern has been growing over the German biotech's progress in bringing its Covid-19 vaccine to market.
BioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets. Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs.
The big shareholder groups in CureVac N.V. ( NASDAQ:CVAC ) have power over the company. Large companies usually have...